Lakewood-Amedex Biotherapeutics Inc. (LABT)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.96M |
| Shares Out | 18.68M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About LABT
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Our product candidates consist of antimicrobials targeting acute and chronic infectious diseases, which are delivered locally to the site of ... [Read more]
News
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.
Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU program SARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., ...
Lakewood-Amedex Biotherapeutics announces new patent in Australia
Lakewood-Amedex Biotherapeutics (LABT) announced the expansion of the company’s patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin compounds that are being explor...
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
New patent enhances global IP footprint and pipeline expansion opportunities SARASOTA, Fla., June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinic...
Lakewood-amedex Biotherapeutics Inc trading halted, news pending
19:50 EDT Lakewood-amedex Biotherapeutics (LABT) Inc trading halted, news pending
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
SARASOTA, Fla., June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting...
Lakewood-Amedex Biotherapeutics building broad antimicrobial platform, CEO says
14:00 EDT Lakewood-Amedex Biotherapeutics (LABT) building broad antimicrobial platform, CEO says
Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper
In an exclusive interview, Lakewood‑Amedex Biotherapeutics (LABT) CEO Kelvin Cooper spoke with The Fly about the company, going public, its Bisphosphocin technology, primary objectives, and more. BISP...
Lakewood-Amedex Biotherapeutics issued two new patents
Lakewood-Amedex Biotherapeutics (LABT) announced an expansion of its global intellectual property portfolio with the issuance of two patents, one each in Australia and New Zealand respectively. The tw...
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patents SARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-...
Lakewood-Amedex Biotherapeutics advances production of foot ulcer candidate Nu3
Lakewood-Amedex Biotherapeutics (LABT) announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildl...
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial SARASOTA, Fla., May 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ...
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU market SARASOTA, Fla., May 12, 2026 /PRNewswire/ -- Lakewood-Amede...
Lakewood-Amedex Biotherapeutics’ lead candidate in foot ulcers shows efficacy
Lakewood-Amedex Biotherapeutics (LABT) announced positive antimicrobial resistance, or AMR, data for its lead compound, Nu-3, which is being developed as a topically delivered treatment for infected d...
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing SARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc.,...
Lakewood-Amedex Biotherapeutics Inc. Common Stock trading halted, volatility trading pause
09:38 EDT Lakewood-Amedex Biotherapeutics (LABT) Inc. Common Stock trading halted, volatility trading pause
Lakewood-Amedex Biotherapeutics Inc. Common Stock trading resumes
09:43 EDT Lakewood-Amedex Biotherapeutics (LABT) Inc. Common Stock trading resumes
Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
SARASOTA, Fla., April 23, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectr...
Lakewood-Amedex Biotherapeutics, Biotech Developing Novel Locally Delivered Antimicrobials for Resistant Infections and Chronic Wounds, Files for Nasdaq Capital Market IPO
Lakewood-Amedex Biotherapeutics filed an S-1 to list its common stock on the Nasdaq Capital Market under the ticker LABT via a direct listing.
Lakewood-Amedex Biotherapeutics IPO Registration Document (S-1)
Lakewood-Amedex Biotherapeutics has filed to go public with an IPO on the NASDAQ
Micro-cap biotech Lakewood-Amedex Biotherapeutics files for a Nasdaq direct listing
Lakewood-Amedex Biotherapeutics, which is developing a topical antimicrobial treatment for drug-resistant infections, filed on Friday for a direct listing on the Nasdaq. The shares of common stock lis...